Real-World Use of Lenvatinib + Pembrolizumab in Patients With pMMR Recurrent EC
Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.
Watch
Treatment Options for pMMR Recurrent EC: KEYNOTE 775
Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.
Watch